Figure 2.Incidence of moderate-to-severe dermatologic adverse events by category and body site during the first 12 weeks of treatmentProphylactic dermatologic management (blue bars) dramatically reduced the occurrence of significant rash on the face/body and scalp, and slightly reduced nail inflammation, compared to standard reactive care (gray bars). Each bar represents the percentage of patients withgrade ≥2 AEs in that category (e.g., acneiform rash on face/body, scalp AEs, or paronychia). Prophylaxis conferred a 63% reduction in face/body rash and a 69% reduction in scalp AEs. All differences shown favored the COCOON prophylaxis arm.
